Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 20/20 | 0.58 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.58 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olpadronic Acid SCHEMBL232124 | 0.98 | FDPS (0.56) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| Olpadronic Acid SCHEMBL9581942 | 0.90 | FDPS (0.69) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL12631211 | 0.89 | FDPS (0.49) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| Olpadronic Acid SCHEMBL7457593 | 0.87 | FDPS (0.71) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL3976360 | 0.86 | FDPS (0.57) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| Olpadronic Acid SCHEMBL5717996 | 0.86 | FDPS (0.55) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL9333595 | 0.85 | FDPS (0.61) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL8050318 | 0.84 | FDPS (0.45) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL16091938 | 0.83 | FDPS (0.62) | FDPSGGPS1PDE3AAGTR1OPRM1 | |
| SCHEMBL9333367 | 0.83 | FDPS (0.62) | FDPSGGPS1PDE3AAGTR1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2429 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102414-A1 | USE OF DERIVATIVES CONTAINING C-O-P BONDS IN PATIENTS WITH KIDNEY FAILURE | SANIFIT THERAPEUTICS S A (ES) | 2026-04-16 | — | — | US | claimed |
| US-12569507-B2 | CAR T-cells for the treatment of bone metastatic cancer | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | claimed |
| EP-4684811-A1 | NOVEL TREATMENT REGIMEN AND METHODS IN BONE HEALING | Moroxite AB (SE) | 2026-01-28 | — | — | EP | claimed |
| WO-2025261951-A1 | COMBINATION THERAPY WITH AN ANTI-CA19-9 ANTIBODY AND FOLFIRINOX IN THE TREATMENT OF CANCER | BioNTech SE (DE) | 2025-12-26 | — | — | WO | claimed |
| US-20250295676-A1 | INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, INHIBITING THE PROGRESSION, OR PREVENTING CARDIOVASCULAR CALCIFICATION | VIFOR (INTERNATIONAL) LTD. (CH) | 2025-09-25 | — | — | US | claimed |
| EP-4611104-A1 | NON-AQUEOUS ELECTROLYTE, SODIUM-ION BATTERY CONTAINING SAME, AND ELECTRICAL APPARATUS | Contemporary Amperex Technology (Hong Kong) Limited (HK) | 2025-09-03 | — | — | EP | claimed |
| EP-3901283-B1 | THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS | INBIOMOTION SL (ES) | 2025-08-06 | — | — | EP | claimed |
| US-12359191-B2 | Polyanionic acids to improve recovery and minimize system loss | WATERS TECHNOLOGIES CORPORATION (US) | 2025-07-15 | — | — | US | claimed |
| US-20250219149-A1 | NON-AQUEOUS ELECTROLYTE AND SODIUM-ION BATTERY AND ELECTRIC APPARATUS INCLUDING SUCH ELECTROLYTE | CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) | 2025-07-03 | — | — | US | claimed |
| CN-119656381-B | Active organic-inorganic composite implant material and preparation method and application thereof | 广东粤港澳大湾区黄埔材料研究院 | 2025-06-13 | — | — | CN | claimed |
| US-5358941-A | Treatment of bone disorders, osteoporosis | MERCK & CO., INC. (US) | 1994-10-25 | — | — | US | claimed |
| WO-1994012200-A1 | DRY MIX FORMULATION FOR BISPHOSPHONIC ACIDS | MERCK & CO., INC. (US) | 1994-06-09 | — | — | WO | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| US-5296475-A | Methanediphosphonic acids and crown compounds for treatment of bone disorders or hypercalcemia | CIBA-GEIGY CORPORATION (US) | 1994-03-22 | — | — | US | claimed |
| WO-1994000129-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| US-5139786-A | Topical formulations | CIBA-GEIGY CORPORATION (US) | 1992-08-18 | — | — | US | claimed |
| EP-0407345-A2 | Topical formulations | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| EP-0401243-A1 | MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES. | HENKEL KGAA (DE) | 1990-12-12 | — | — | EP | claimed |
| WO-1989007453-A1 | MEDICINAL PREPARATIONS CHARACTERIZED BY A COMBINATION OF CYTOSTATIC AGENTS, HORMONAL THERAPEUTIC AGENTS AND PHOSPHONE DERIVATIVES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1989-08-24 | — | — | WO | claimed |